Brii Biosciences Confirms Its Antibody Cocktail Holds Its Own Against Omicron
In a Big Win for China’s COVID‑19 Arsenal
Beijing – Brii Biosciences dropped some fresh 2024 news: its newly approved antibody cocktail still fights the Omicron variant pretty well. Only one of the two antibodies that make up the mix saw a noticeable dip when tested on its own.
Lab‑Proof that the Duo Packs a Punch
Three independent labs all found a similar pattern, says CEO Hong Zhi during a Monday investor call. The full details of the tests won’t be public until the next scientific journal comes out, but the data suggests the cocktail can keep up with the sneaky Omicron strain.
Manufacturing Numbers: Its Big‑Business Moves
- Hundreds of millions of doses? Not yet. But Brii has already set up production slots for one million doses in both 2022 and 2023.
- Inventory check: About 80 000 doses are sitting ready in stock.
- Manufacturing partner: WuXi Biologics is handling the biotech heavy lifting.
Looking Ahead: Stockpiling and Cash Flow
Hong highlighted that while no official purchase orders have popped up yet, the company is shooting for stockpiling contracts. “It’s essential for a small player to keep the cash flowing while hitting the pandemic head-on,” he said.
Why It Matters
Brii’s cocktail stepping forward as China’s first antibody treatment approval is a milestone. It shows that even amid concerns about vaccine escape, another weapon can still hold its ground and help protect communities.
—.
